Developer docs
API playgroundTry for free, no card

Search company profiles

PharmaLogic Holdings

Full company profile

uuid0006sbx

Namestring
PharmaLogic Holdings
Legal namestring
PharmaLogic Holdings Corp.
Company typeenum
Private
Founded yearint
1993
Descriptiontext

PharmaLogic Holdings Corp. is a privately held radiopharmaceutical Contract Development and Manufacturing Organization (CDMO) and Contract Manufacturing Organization (CMO) founded in 1993 and headquartered in Boca Raton, Florida. The company delivers end-to-end Chemistry, Manufacturing, and Controls (CMC) and technical capabilities that enable pharmaceutical sponsors to advance diagnostic and therapeutic radiopharmaceutical products from clinical development through commercial launch. Its four core service lines are CDMO Services, CMO Diagnostics (including PET drug manufacturing), CMO Therapeutics (including Actinium-225-based targeted radiotherapeutics for cancer), and Supply Chain & Radiopharmacy distribution.

Operationally, PharmaLogic runs a multi-site U.S. manufacturing network spanning Atlanta, Georgia (a $250 million facility opened in April 2026), Idaho Falls, the Bronx, Cincinnati, Salt Lake City, Los Angeles, and New York, with international capacity added through the 2024 majority acquisition of Norway-based Agilera Pharma. The infrastructure is purpose-built for short-half-life radiopharmaceuticals that require just-in-time production and regional distribution to hospitals and imaging centers. PharmaLogic operates under FDA Part 212 quality standards as a PET drug manufacturer.

The company is sales-led and B2B, serving two primary segments: pharmaceutical sponsors requiring radiopharmaceutical contract development and manufacturing, and hospitals and imaging centers requiring reliable diagnostic supply. Revenue is generated through managed-services contracts with quote-based, project-negotiated pricing. PharmaLogic is led by CEO Etienne Montagut, with Steve Chilinski as Executive Chairman and D. Scott Holbrook as GM and Chief Strategy Officer.

Short descriptiontext

PharmaLogic Holdings is a privately held U.S. radiopharmaceutical CDMO/CMO operating multiple manufacturing facilities that provide CMC, production, and supply chain services for diagnostic and therapeutic radiopharmaceuticals to pharmaceutical sponsors, hospitals, and imaging centers.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersEvansville, United States
HQ citystring
Evansville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices6 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
radiopharmaceutical manufacturing, contract development services, PET drug production, radiopharmacy distribution, therapeutic radiopharmaceuticals
Industry3 codes
PRIMARYHLAIAGAF
Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYEUAKAIAC
Radiopharmaceutical Manufacturing & CDMO (Synthesis, GMP, Packaging, QA/QC)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Radiopharmaceutical CDMO/CMO Services
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model4 records
1CDMO Services
TypeManaged Services
Description

Contract development and manufacturing services for radiopharmaceuticals, supporting drug development from clinical stages through commercial launch with CMC and technical capabilities

pharmalogicgroup.com
2CMO Diagnostics
TypeManaged Services
Description

Contract manufacturing organization services for diagnostic radiopharmaceuticals

pharmalogicgroup.com
3CMO Therapeutics
TypeManaged Services
Description

Contract manufacturing organization services for therapeutic radiopharmaceuticals

pharmalogicgroup.com
4Supply Chain & Radiopharmacy Services
TypeManaged Services
Description

Supply chain management and radiopharmacy services supporting distribution of time-sensitive radiopharmaceuticals

pharmalogicgroup.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Infrastructure, Personnel, Operations, Technology or R&D, Supply Chain
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

PharmaLogic Holdings is a Contract Development and Manufacturing Organization (CDMO/CMO) specializing in radiopharmaceuticals. It provides end-to-end CMC and technical capabilities for diagnostic and therapeutic radiopharmaceuticals from clinical development through commercial launch, including just-in-time manufacturing, supply chain management, and radiopharmacy distribution to hospitals and imaging centers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Expanded manufacturing capacity to support larger-scale multi-dose batch production for clinical and potentially registrational trials
Product overview1 text field

PharmaLogic Holdings operates as a Contract Development and Manufacturing Organization (CDMO) and Contract Manufacturing Organization (CMO) specializing in radiopharmaceuticals. The company offers four core service offerings: CDMO Services providing end-to-end CMC and technical capabilities from clinical development through commercial launch; CMO Diagnostics for PET drug manufacturing; CMO Therapeutics for therapeutic radiopharmaceuticals including Actinium-225 based products; and Supply Chain & Radiopharmacy services for distribution of time-sensitive products. The company operates multiple manufacturing facilities across the United States including locations in Atlanta, Georgia, Idaho Falls, Idaho, Bronx, New York, Cincinnati, Salt Lake City, and Los Angeles. PharmaLogic supports pharmaceutical partners like Ratio Therapeutics in clinical supply and commercialization of targeted radiopharmaceuticals for cancer treatment.

Product and service4 records
1CDMO Services
CategoryContract Development & Manufacturing
Description

Contract Development and Manufacturing Operations services delivering a suite of CMC and technical capabilities to support drug sponsors developing diagnostic and therapeutic radiopharmaceuticals from clinical development through commercial launch.

2CMO Diagnostics
CategoryContract Manufacturing
Description

Contract Manufacturing Operations for diagnostic radiopharmaceuticals, supporting production of PET drugs and imaging agents for diagnostic applications at hospitals and imaging centers.

3CMO Therapeutics
CategoryContract Manufacturing
Description

Contract Manufacturing Operations for therapeutic radiopharmaceuticals, including Actinium-225 based targeted radiotherapeutics for cancer treatment, supporting larger-scale multi-dose batch production.

4Supply Chain & Radiopharmacy
CategoryDistribution & Logistics
Description

Integrated supply chain and radiopharmacy services enabling just-in-time distribution of time-sensitive radiopharmaceuticals to hospitals and imaging centers across regional markets.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-05-29
Description

Expanded manufacturing partnership to support clinical development and future commercialization readiness of [Ac-225]RTX-2358, a FAP-targeted therapeutic radiopharmaceutical for cancer treatment. PharmaLogic increases manufacturing capacity at its Idaho Falls facility and implements process enhancements for larger multi-dose batch production. The collaboration supports ongoing Phase 1/2 ATLAS trial for relapsed or refractory soft tissue sarcoma and positions the program for later-stage and potentially registrational trials.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

GE HealthCare offers radiopharmaceutical manufacturing and PET radiotracer products as part of its broader imaging and diagnostics portfolio. It is a large, diversified incumbent whose radiopharma business overlaps with PharmaLogic's CMO Diagnostics offering.

TypeDirect peer
Description

Lantheus is a radiopharmaceutical-focused company with both proprietary products and contract manufacturing capabilities for diagnostic and therapeutic agents. It is a direct peer in the radiopharma CDMO/CMO space and competes for the same pharmaceutical sponsor relationships.

TypeEmerging player
Description

Bracco manufactures diagnostic imaging agents and contrast media with growing activity in radiopharmaceuticals. It is comparable to PharmaLogic as an adjacent diagnostics manufacturer expanding into nuclear medicine.

TypeEmerging player
Description

SOFIE was a theranostics-focused radiopharma manufacturer and radiopharmacy operator before being acquired by Cardinal Health. It represents the kind of emerging, specialized radiopharma manufacturer competing for the same therapeutic CDMO business PharmaLogic targets.

TypeEmerging player
Description

Telix develops and manufactures its own theranostic radiopharmaceuticals (e.g., Illuccix) and operates manufacturing infrastructure. It overlaps with PharmaLogic both as a potential sponsor-customer and as an emerging competitor in targeted radiotherapeutics and PSMA imaging agents.

TypeDirect peer
Description

Curium is one of the world's largest nuclear medicine companies, manufacturing SPECT, PET, and therapeutic radiopharmaceuticals globally. It competes head-on with PharmaLogic across both diagnostic and therapeutic CDMO/CMO services.

TypeDirect peer
Description

Cardinal Health operates the largest radiopharmacy network in the U.S., distributing PET and SPECT agents to hospitals and imaging centers. Its nuclear pharmacy services directly overlap with PharmaLogic's Supply Chain & Radiopharmacy offering.

TypeDirect peer
Description

Jubilant operates one of the largest commercial radiopharmaceutical manufacturing networks, supplying nuclear medicine products across the U.S. and internationally. It directly competes with PharmaLogic in radiopharmacy distribution and contract manufacturing.

TypeDirect peer
Description

PETNET operates the largest U.S. network of PET radiopharmacy manufacturing and distribution centers. It is the closest direct competitor to PharmaLogic's CDMO + radiopharmacy model, serving the same hospital and imaging-center customer base with short-half-life diagnostic radiopharmaceuticals.

TypeDirect peer
Description

IBA Molecular was a major global radiopharmaceutical manufacturer (now integrated into Curium) and competed directly with PharmaLogic in PET and SPECT agent manufacturing for hospital and clinical customers.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

PharmaLogic Holdings

Radiopharmaceutical CDMO/CMO Servicesradiopharmacy.com

PharmaLogic Holdings is a privately held U.S. radiopharmaceutical CDMO/CMO operating multiple manufacturing facilities that provide CMC, production, and supply chain services for diagnostic and therapeutic radiopharmaceuticals to pharmaceutical sponsors, hospitals, and imaging centers.

What PharmaLogic Holdings does

PharmaLogic Holdings Corp. is a privately held radiopharmaceutical Contract Development and Manufacturing Organization (CDMO) and Contract Manufacturing Organization (CMO) founded in 1993 and headquartered in Boca Raton, Florida. The company delivers end-to-end Chemistry, Manufacturing, and Controls (CMC) and technical capabilities that enable pharmaceutical sponsors to advance diagnostic and therapeutic radiopharmaceutical products from clinical development through commercial launch. Its four core service lines are CDMO Services, CMO Diagnostics (including PET drug manufacturing), CMO Therapeutics (including Actinium-225-based targeted radiotherapeutics for cancer), and Supply Chain & Radiopharmacy distribution.

Operationally, PharmaLogic runs a multi-site U.S. manufacturing network spanning Atlanta, Georgia (a $250 million facility opened in April 2026), Idaho Falls, the Bronx, Cincinnati, Salt Lake City, Los Angeles, and New York, with international capacity added through the 2024 majority acquisition of Norway-based Agilera Pharma. The infrastructure is purpose-built for short-half-life radiopharmaceuticals that require just-in-time production and regional distribution to hospitals and imaging centers. PharmaLogic operates under FDA Part 212 quality standards as a PET drug manufacturer.

The company is sales-led and B2B, serving two primary segments: pharmaceutical sponsors requiring radiopharmaceutical contract development and manufacturing, and hospitals and imaging centers requiring reliable diagnostic supply. Revenue is generated through managed-services contracts with quote-based, project-negotiated pricing. PharmaLogic is led by CEO Etienne Montagut, with Steve Chilinski as Executive Chairman and D. Scott Holbrook as GM and Chief Strategy Officer.

PharmaLogic Holdings firmographics

Firmographics
Name
PharmaLogic Holdings
Legal name
PharmaLogic Holdings Corp.
Website
https://radiopharmacy.com
Company type
Private
Founded year
1993
Operating status
Operating
Headcount range
11–50 employees
Short description
PharmaLogic Holdings is a privately held U.S. radiopharmaceutical CDMO/CMO operating multiple manufacturing facilities that provide CMC, production, and supply chain services for diagnostic and therapeutic radiopharmaceuticals to pharmaceutical sponsors, hospitals, and imaging centers.
Ownership category
akta.pro rank

PharmaLogic Holdings industry classification

Industry
Product category
Radiopharmaceutical CDMO/CMO Services
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIAGAF
Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
SECONDARYEUAKAIAC
Radiopharmaceutical Manufacturing & CDMO (Synthesis, GMP, Packaging, QA/QC)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Radiopharmaceutical manufacturing
  • Contract development services
  • PET drug production
  • Radiopharmacy distribution
  • Therapeutic radiopharmaceuticals

Where PharmaLogic Holdings is headquartered

Location

Headquarters

HQ city
Evansville
HQ country
United States
HQ region
North America

Offices6 records

Markets served

PharmaLogic Holdings business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Infrastructure, Personnel, Operations, Technology or R&D, Supply Chain

Revenue model

  1. CDMO Services: Contract development and manufacturing services for radiopharmaceuticals, supporting drug development from clinical stages through commercial launch with CMC and technical capabilities
  2. CMO Diagnostics: Contract manufacturing organization services for diagnostic radiopharmaceuticals
  3. CMO Therapeutics: Contract manufacturing organization services for therapeutic radiopharmaceuticals
  4. Supply Chain & Radiopharmacy Services: Supply chain management and radiopharmacy services supporting distribution of time-sensitive radiopharmaceuticals

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

PharmaLogic Holdings product offering

Product offering

Core offering

PharmaLogic Holdings is a Contract Development and Manufacturing Organization (CDMO/CMO) specializing in radiopharmaceuticals. It provides end-to-end CMC and technical capabilities for diagnostic and therapeutic radiopharmaceuticals from clinical development through commercial launch, including just-in-time manufacturing, supply chain management, and radiopharmacy distribution to hospitals and imaging centers.

Product overview

PharmaLogic Holdings operates as a Contract Development and Manufacturing Organization (CDMO) and Contract Manufacturing Organization (CMO) specializing in radiopharmaceuticals. The company offers four core service offerings: CDMO Services providing end-to-end CMC and technical capabilities from clinical development through commercial launch; CMO Diagnostics for PET drug manufacturing; CMO Therapeutics for therapeutic radiopharmaceuticals including Actinium-225 based products; and Supply Chain & Radiopharmacy services for distribution of time-sensitive products. The company operates multiple manufacturing facilities across the United States including locations in Atlanta, Georgia, Idaho Falls, Idaho, Bronx, New York, Cincinnati, Salt Lake City, and Los Angeles. PharmaLogic supports pharmaceutical partners like Ratio Therapeutics in clinical supply and commercialization of targeted radiopharmaceuticals for cancer treatment.

Differentiator

Problem solved

Functional benefit

Products and services

  • CDMO Services Contract Development and Manufacturing Operations services delivering a suite of CMC and technical capabilities to support drug sponsors developing diagnostic and therapeutic radiopharmaceuticals from clinical development through commercial launch.
  • CMO Diagnostics Contract Manufacturing Operations for diagnostic radiopharmaceuticals, supporting production of PET drugs and imaging agents for diagnostic applications at hospitals and imaging centers.
  • CMO Therapeutics Contract Manufacturing Operations for therapeutic radiopharmaceuticals, including Actinium-225 based targeted radiotherapeutics for cancer treatment, supporting larger-scale multi-dose batch production.
  • Supply Chain & Radiopharmacy Integrated supply chain and radiopharmacy services enabling just-in-time distribution of time-sensitive radiopharmaceuticals to hospitals and imaging centers across regional markets.

Quantifiable outcome

  • Expanded manufacturing capacity to support larger-scale multi-dose batch production for clinical and potentially registrational trials

Companies that use PharmaLogic Holdings

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

PharmaLogic Holdings technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

PharmaLogic Holdings partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Ratio Therapeutics Inc.coreStrategic or Co-development Partner · 29 May 2026Expanded manufacturing partnership to support clinical development and future commercialization readiness of [Ac-225]RTX-2358, a FAP-targeted therapeutic radiopharmaceutical for cancer treatment. PharmaLogic increases manufacturing capacity at its Idaho Falls facility and implements process enhancements for larger multi-dose batch production. The collaboration supports ongoing Phase 1/2 ATLAS trial for relapsed or refractory soft tissue sarcoma and positions the program for later-stage and potentially registrational trials.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

PharmaLogic Holdings competitors and assessment

Company assessment

Broad incumbents

  • GE HealthCare: GE HealthCare offers radiopharmaceutical manufacturing and PET radiotracer products as part of its broader imaging and diagnostics portfolio. It is a large, diversified incumbent whose radiopharma business overlaps with PharmaLogic's CMO Diagnostics offering.

Direct peers

  • Lantheus Holdings: Lantheus is a radiopharmaceutical-focused company with both proprietary products and contract manufacturing capabilities for diagnostic and therapeutic agents. It is a direct peer in the radiopharma CDMO/CMO space and competes for the same pharmaceutical sponsor relationships.
  • Curium Pharma: Curium is one of the world's largest nuclear medicine companies, manufacturing SPECT, PET, and therapeutic radiopharmaceuticals globally. It competes head-on with PharmaLogic across both diagnostic and therapeutic CDMO/CMO services.
  • Cardinal Health (Nuclear & Precision Health Solutions): Cardinal Health operates the largest radiopharmacy network in the U.S., distributing PET and SPECT agents to hospitals and imaging centers. Its nuclear pharmacy services directly overlap with PharmaLogic's Supply Chain & Radiopharmacy offering.
  • Jubilant Radiopharma: Jubilant operates one of the largest commercial radiopharmaceutical manufacturing networks, supplying nuclear medicine products across the U.S. and internationally. It directly competes with PharmaLogic in radiopharmacy distribution and contract manufacturing.
  • PETNET Solutions (Siemens Healthineers): PETNET operates the largest U.S. network of PET radiopharmacy manufacturing and distribution centers. It is the closest direct competitor to PharmaLogic's CDMO + radiopharmacy model, serving the same hospital and imaging-center customer base with short-half-life diagnostic radiopharmaceuticals.
  • IBA Molecular (now part of Curium): IBA Molecular was a major global radiopharmaceutical manufacturer (now integrated into Curium) and competed directly with PharmaLogic in PET and SPECT agent manufacturing for hospital and clinical customers.

Emerging players

  • Bracco Imaging: Bracco manufactures diagnostic imaging agents and contrast media with growing activity in radiopharmaceuticals. It is comparable to PharmaLogic as an adjacent diagnostics manufacturer expanding into nuclear medicine.
  • SOFIE Biosciences (acquired by Cardinal Health): SOFIE was a theranostics-focused radiopharma manufacturer and radiopharmacy operator before being acquired by Cardinal Health. It represents the kind of emerging, specialized radiopharma manufacturer competing for the same therapeutic CDMO business PharmaLogic targets.
  • Telix Pharmaceuticals: Telix develops and manufactures its own theranostic radiopharmaceuticals (e.g., Illuccix) and operates manufacturing infrastructure. It overlaps with PharmaLogic both as a potential sponsor-customer and as an emerging competitor in targeted radiotherapeutics and PSMA imaging agents.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

PharmaLogic Holdings social profiles

Digital presence

PharmaLogic Holdings financial estimates

Financial estimate

Revenue estimate

Valuation estimate

PharmaLogic Holdings leadership team

Management profile

Number of profiles

Profiles3 records

PharmaLogic Holdings subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

PharmaLogic Holdings funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

PharmaLogic Holdings M&A and investment

M&A and investment

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about PharmaLogic Holdings

What does PharmaLogic Holdings do?

PharmaLogic Holdings is a Contract Development and Manufacturing Organization (CDMO/CMO) specializing in radiopharmaceuticals. It provides end-to-end CMC and technical capabilities for diagnostic and therapeutic radiopharmaceuticals from clinical development through commercial launch, including just-in-time manufacturing, supply chain management, and radiopharmacy distribution to hospitals and imaging centers.

Is PharmaLogic Holdings a public or private company?

PharmaLogic Holdings is a private company. It is classified as unknown and is currently operating.

When was PharmaLogic Holdings founded?

PharmaLogic Holdings was founded in 1993. It employs 11 to 50 people.

Where is PharmaLogic Holdings based?

PharmaLogic Holdings is headquartered in Evansville, United States, in the North America region.

How does PharmaLogic Holdings make money?

Four revenue lines are on record. CDMO Services are the primary driver. The others are CMO Diagnostics, CMO Therapeutics and supply Chain & Radiopharmacy Services.

Who are PharmaLogic Holdings's main competitors?

GE HealthCare is listed as a broad incumbent. Direct peers are Lantheus Holdings, Curium Pharma, Cardinal Health (Nuclear & Precision Health Solutions), Jubilant Radiopharma, PETNET Solutions (Siemens Healthineers) and IBA Molecular (now part of Curium). Emerging players are Bracco Imaging, SOFIE Biosciences (acquired by Cardinal Health) and Telix Pharmaceuticals.

Does PharmaLogic Holdings have an API?

No public API is recorded for PharmaLogic Holdings.

What industry is PharmaLogic Holdings in?

PharmaLogic Holdings's product category is Radiopharmaceutical CDMO/CMO Services. Its primary akta.pro industry code is HLAIAGAF, Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish), with a secondary code of EUAKAIAC, Radiopharmaceutical Manufacturing & CDMO (Synthesis, GMP, Packaging, QA/QC). Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BioSpacePharmaLogic buys Lantheus plant to build transatlantic radiopharmaceutical CDMOPharmaLogic agreed to buy Lantheus's radiopharmaceutical CDMO and a New Jersey plant for an undisclosed sum. The Springfield facility, completed in 2021, will support transatlantic production, and employees will join Agilera Pharma. Lantheus is selling the assets while pursuing its merger with Curium, closing in 2027.MarketWatchPharmaLogic Agrees to Buy Lantheus' CDMO Business, N.J. FacilityPharmaLogic agreed to acquire Lantheus Holdings' contract development and manufacturing organization business and a Springfield, N.J. facility. The deal includes a long-term agreement for Agilera to supply lutetium Lu 177 dotatate to Lantheus. Financial terms were not disclosed.PR NewswirePharmaLogic announces opening of new PET radiopharmaceutical manufacturing facility in Atlanta, GeorgiaPharmaLogic Holdings Corp. announced the opening of its new PET radiopharmaceutical manufacturing facility in Atlanta, Georgia, representing a $250 million investment to expand domestic radiopharmaceutical manufacturing infrastructure. The state-of-the-art facility is designed to expand production capacity, accelerate research and development of novel radiopharmaceuticals, and enable faster distribution of time-sensitive radiopharmaceuticals to hospitals and imaging centers across the Southeast region. The Atlanta opening continues PharmaLogic's national expansion strategy following recent facility openings in Cincinnati, Bronx, Salt Lake City, and Los Angeles.openPR.comRadiopharmaceuticals CDMO/CMO Services Market Advanced Market Intelligence Report 2026 to 2035The global radiopharmaceuticals CDMO/CMO services market is projected to reach over USD 7.0 billion by 2035, growing at a CAGR of 9.2% during the forecast period, driven by increasing cancer prevalence, rising therapeutic applications, and growing investments in the biotechnology and pharmaceutical industries. In May 2024, PharmaLogic Holdings Corp. launched a radiopharmaceutical production and research facility in New York, expanding its contract development and manufacturing operations. Market growth is expected to be tempered by high service costs and limited awareness in developing countries.BioSpacePharmaLogic Announces Successful Supply of First Cohort Dosing for Ratio Therapeutics’ Phase 1/2 Study of a Novel FAP-Targeted Radiopharmaceutical in Late-Stage Aggressive SarcomasPharmaLogic Holdings Corp. announced successful manufacturing and delivery of the first cohort dosing for Ratio Therapeutics' Phase 1/2 ATLAS clinical trial of [Ac-225]-RTX-2358, a FAP-targeted radiopharmaceutical labeled with Actinium 225 for treating relapsed or refractory soft tissue sarcomas. The dose was produced at PharmaLogic's radiopharmaceutical manufacturing facility in Bronx, New York. The ATLAS trial will assess safety, tolerability, and preliminary anti-tumor activity in up to 26 patients during Phase 1 using a 3+3 dose escalation design, with Phase 2 planned for up to 50 patients.PR NewswirePharmaLogic Completes Acquisition of Majority Stake in Agilera Pharma ASPharmaLogic completed its acquisition of a majority stake in Agilera Pharma AS from Norway's IFE. The deal expands PharmaLogic's radiopharmaceutical CDMO capabilities and distribution across over 30 countries. Agilera, spun off from IFE in 2023, has 140 employees and operates CDMO, CMO, and wholesaler services.UPMCEnabling a New Era of Advanced Therapeutics at UPMCUPMC Enterprises is partnering with PharmaLogic Holdings Corp. to construct a major radiopharmaceutical production facility in Pittsburgh, while also collaborating with ElevateBio on the Pitt BioForge Biomanufacturing Center to support cell and gene therapies. These strategic investments aim to overcome logistical and manufacturing barriers to advanced therapeutics, thereby improving patient access and establishing UPMC as a leader in this sector.PR NewswirePharmaLogic announces opening of radiopharmaceutical production facility in Los AngelesPharmaLogic Holdings Corp. officially opened its radiopharmaceutical production and research facility in Los Angeles, California, following its acquisition in 2022 and extensive renovations. The facility, equipped with state-of-the-art equipment, represents a major investment in manufacturing and research capabilities, enabling collaboration with leading healthcare providers and researchers to develop novel radiopharmaceuticals and expand patient access to diagnostic technologies.MorningstarRatio Announces Expansion of Manufacturing Agreement with PharmaLogic for FAP-Targeted RadiopharmaceuticalsRatio Therapeutics expanded its manufacturing agreement with PharmaLogic for FAP-targeted radiopharmaceuticals. The company also announced a $50M Series B financing to advance its first FAP-targeted therapeutic candidate into clinical trials this year.YahooRatio Announces Expansion of Manufacturing Agreement with PharmaLogic for FAP-Targeted RadiopharmaceuticalsRatio Therapeutics expanded its manufacturing agreement with PharmaLogic for FAP-targeted radiopharmaceuticals. The company also announced a $50M Series B financing to advance its first FAP-targeted therapeutic candidate into clinical trials this year.